GeneDx Holdings Statistics
Total Valuation
GeneDx Holdings has a market cap or net worth of $2.97 billion. The enterprise value is $2.94 billion.
Important Dates
The next confirmed earnings date is Wednesday, April 30, 2025, before market open.
| Earnings Date | Apr 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GeneDx Holdings has 28.07 million shares outstanding. The number of shares has increased by 10.61% in one year.
| Current Share Class | 28.07M |
| Shares Outstanding | 28.07M |
| Shares Change (YoY) | +10.61% |
| Shares Change (QoQ) | +2.54% |
| Owned by Insiders (%) | 1.53% |
| Owned by Institutions (%) | 65.88% |
| Float | 18.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 114.88 |
| PS Ratio | 9.30 |
| Forward PS | 8.20 |
| PB Ratio | 12.07 |
| P/TBV Ratio | 34.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.63 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.61, with a Debt / Equity ratio of 0.47.
| Current Ratio | 3.61 |
| Quick Ratio | 3.26 |
| Debt / Equity | 0.47 |
| Debt / EBITDA | 17.38 |
| Debt / FCF | n/a |
| Interest Coverage | -7.08 |
Financial Efficiency
Return on equity (ROE) is -22.10% and return on invested capital (ROIC) is -3.79%.
| Return on Equity (ROE) | -22.10% |
| Return on Assets (ROA) | -3.20% |
| Return on Invested Capital (ROIC) | -3.79% |
| Return on Capital Employed (ROCE) | -5.89% |
| Revenue Per Employee | $305,450 |
| Profits Per Employee | -$52,286 |
| Employee Count | 1,000 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 11.43 |
Taxes
| Income Tax | -343,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +917.23% in the last 52 weeks. The beta is 2.00, so GeneDx Holdings's price volatility has been higher than the market average.
| Beta (5Y) | 2.00 |
| 52-Week Price Change | +917.23% |
| 50-Day Moving Average | 93.91 |
| 200-Day Moving Average | 66.01 |
| Relative Strength Index (RSI) | 60.12 |
| Average Volume (20 Days) | 846,514 |
Short Selling Information
The latest short interest is 2.76 million, so 9.84% of the outstanding shares have been sold short.
| Short Interest | 2.76M |
| Short Previous Month | 2.49M |
| Short % of Shares Out | 9.84% |
| Short % of Float | 14.92% |
| Short Ratio (days to cover) | 3.86 |
Income Statement
In the last 12 months, GeneDx Holdings had revenue of $305.45 million and -$52.29 million in losses. Loss per share was -$1.94.
| Revenue | 305.45M |
| Gross Profit | 194.45M |
| Operating Income | -21.46M |
| Pretax Income | -118.33M |
| Net Income | -52.29M |
| EBITDA | -408,000 |
| EBIT | -21.46M |
| Loss Per Share | -$1.94 |
Full Income StatementBalance Sheet
The company has $141.19 million in cash and $116.17 million in debt, giving a net cash position of $25.02 million or $0.89 per share.
| Cash & Cash Equivalents | 141.19M |
| Total Debt | 116.17M |
| Net Cash | 25.02M |
| Net Cash Per Share | $0.89 |
| Equity (Book Value) | 245.25M |
| Book Value Per Share | 8.75 |
| Working Capital | 143.15M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$28.50 million and capital expenditures -$5.49 million, giving a free cash flow of -$33.99 million.
| Operating Cash Flow | -28.50M |
| Capital Expenditures | -5.49M |
| Free Cash Flow | -33.99M |
| FCF Per Share | -$1.21 |
Full Cash Flow StatementMargins
Gross margin is 63.66%, with operating and profit margins of -7.03% and -17.12%.
| Gross Margin | 63.66% |
| Operating Margin | -7.03% |
| Pretax Margin | -17.23% |
| Profit Margin | -17.12% |
| EBITDA Margin | -0.13% |
| EBIT Margin | -7.03% |
| FCF Margin | n/a |
Dividends & Yields
GeneDx Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.61% |
| Shareholder Yield | -10.61% |
| Earnings Yield | -1.76% |
| FCF Yield | -1.15% |
Analyst Forecast
The average price target for GeneDx Holdings is $82.60, which is -21.85% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $82.60 |
| Price Target Difference | -21.85% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on May 4, 2023. It was a reverse split with a ratio of 0.030303:1.
| Last Split Date | May 4, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.030303:1 |
Scores
GeneDx Holdings has an Altman Z-Score of -0.53 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.53 |
| Piotroski F-Score | 5 |